Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023952431> ?p ?o ?g. }
- W2023952431 endingPage "625" @default.
- W2023952431 startingPage "619" @default.
- W2023952431 abstract "fewer than half of patients infected with hepatitis C virus (HCV) achieve sustained viral clearance after peginterferon alfa/ribavirin (Peg-IFN/RBV) therapy.thalidomide posses anti-inflammatory and immunomodulatory properties through inhibition of tumor necrosis factor and costimulatory effect on human CD8+ T cells.we started a prospective, open label trial of retreatment of very-difficult-to-treat genotype 1 chronic hepatitis C patients (CHC) patients, who had failed to respond to the (Peg-IFN/RBV), with a triple therapy consisting in these same antivirals plus thalidomide 200 mg/day (the TRITAL study).none of the eleven patients fulfilling the inclusion criteria and included in the trial reached complete early virological response or sustained virological response. Viral load decline after 12 weeks of triple therapy thalidomide-based retreatment did not differ from viral dynamics during the first course. The triple therapy was well tolerated and only one patient developed mild bilateral neuropathy.thalidomide addition to standard therapy is tolerated and did not increase the SVR rate in very-difficult-to-treat genotype 1 CHC patients. Different schedules are warranted to improve attempting retreatment of non responder CHC patients." @default.
- W2023952431 created "2016-06-24" @default.
- W2023952431 creator A5002217316 @default.
- W2023952431 creator A5003199280 @default.
- W2023952431 creator A5013708277 @default.
- W2023952431 creator A5028328477 @default.
- W2023952431 creator A5037480677 @default.
- W2023952431 creator A5038420824 @default.
- W2023952431 creator A5042460019 @default.
- W2023952431 creator A5063440729 @default.
- W2023952431 creator A5071565406 @default.
- W2023952431 date "2011-12-01" @default.
- W2023952431 modified "2023-10-16" @default.
- W2023952431 title "Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept" @default.
- W2023952431 cites W1499288756 @default.
- W2023952431 cites W1538219206 @default.
- W2023952431 cites W1553011358 @default.
- W2023952431 cites W1590300762 @default.
- W2023952431 cites W1744784309 @default.
- W2023952431 cites W1939121468 @default.
- W2023952431 cites W1964466523 @default.
- W2023952431 cites W1975655020 @default.
- W2023952431 cites W1976575269 @default.
- W2023952431 cites W1979619419 @default.
- W2023952431 cites W1988898930 @default.
- W2023952431 cites W2001475227 @default.
- W2023952431 cites W2005695219 @default.
- W2023952431 cites W2017698354 @default.
- W2023952431 cites W2020489631 @default.
- W2023952431 cites W2021070836 @default.
- W2023952431 cites W2025360041 @default.
- W2023952431 cites W2026067734 @default.
- W2023952431 cites W2026543492 @default.
- W2023952431 cites W2027650820 @default.
- W2023952431 cites W2034643046 @default.
- W2023952431 cites W2037646730 @default.
- W2023952431 cites W2039041144 @default.
- W2023952431 cites W2058142248 @default.
- W2023952431 cites W2070000479 @default.
- W2023952431 cites W2071277949 @default.
- W2023952431 cites W2074878517 @default.
- W2023952431 cites W2076115977 @default.
- W2023952431 cites W2078674830 @default.
- W2023952431 cites W2080132404 @default.
- W2023952431 cites W2083785084 @default.
- W2023952431 cites W2085261733 @default.
- W2023952431 cites W2106222233 @default.
- W2023952431 cites W2113014631 @default.
- W2023952431 cites W2120153539 @default.
- W2023952431 cites W2124182278 @default.
- W2023952431 cites W2127486203 @default.
- W2023952431 cites W2133802811 @default.
- W2023952431 cites W2134194979 @default.
- W2023952431 cites W2139417546 @default.
- W2023952431 cites W2142614243 @default.
- W2023952431 cites W2162055007 @default.
- W2023952431 cites W2162559503 @default.
- W2023952431 cites W2170033574 @default.
- W2023952431 cites W2170889678 @default.
- W2023952431 cites W2171962335 @default.
- W2023952431 cites W2174322658 @default.
- W2023952431 cites W2414243842 @default.
- W2023952431 cites W2418547501 @default.
- W2023952431 doi "https://doi.org/10.4321/s1130-01082011001200003" @default.
- W2023952431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22217345" @default.
- W2023952431 hasPublicationYear "2011" @default.
- W2023952431 type Work @default.
- W2023952431 sameAs 2023952431 @default.
- W2023952431 citedByCount "4" @default.
- W2023952431 countsByYear W20239524312013 @default.
- W2023952431 countsByYear W20239524312016 @default.
- W2023952431 countsByYear W20239524312017 @default.
- W2023952431 countsByYear W20239524312019 @default.
- W2023952431 crossrefType "journal-article" @default.
- W2023952431 hasAuthorship W2023952431A5002217316 @default.
- W2023952431 hasAuthorship W2023952431A5003199280 @default.
- W2023952431 hasAuthorship W2023952431A5013708277 @default.
- W2023952431 hasAuthorship W2023952431A5028328477 @default.
- W2023952431 hasAuthorship W2023952431A5037480677 @default.
- W2023952431 hasAuthorship W2023952431A5038420824 @default.
- W2023952431 hasAuthorship W2023952431A5042460019 @default.
- W2023952431 hasAuthorship W2023952431A5063440729 @default.
- W2023952431 hasAuthorship W2023952431A5071565406 @default.
- W2023952431 hasBestOaLocation W20239524311 @default.
- W2023952431 hasConcept C126322002 @default.
- W2023952431 hasConcept C142462285 @default.
- W2023952431 hasConcept C203014093 @default.
- W2023952431 hasConcept C2522874641 @default.
- W2023952431 hasConcept C2776364478 @default.
- W2023952431 hasConcept C2776408679 @default.
- W2023952431 hasConcept C2776455275 @default.
- W2023952431 hasConcept C2776999253 @default.
- W2023952431 hasConcept C2779609412 @default.
- W2023952431 hasConcept C2780040827 @default.
- W2023952431 hasConcept C71924100 @default.
- W2023952431 hasConcept C90924648 @default.
- W2023952431 hasConceptScore W2023952431C126322002 @default.
- W2023952431 hasConceptScore W2023952431C142462285 @default.